Theravance Biopharma Inc (TBPH) — Capital Reinvestment Ratio

Latest as of June 2025: 0.00x

Theravance Biopharma Inc (TBPH) has a Capital Reinvestment Ratio of 0.00x as of June 2025, meaning it reinvests 0% of its operating cash flow ($208.07 Million) in capital expenditures ($34.00K). Check TBPH intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.00x
Capex / Operating Cash Flow

Operating Cash Flow

$208.07 Million
USD

Capital Expenditures

$34.00K
USD

Data as of

Jun 2025
Most recent filing

Theravance Biopharma Inc Capital Reinvestment Ratio (2025–2025)

This chart tracks Theravance Biopharma Inc's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see Theravance Biopharma Inc cash flow conversion.

Annual Capital Reinvestment Ratio for Theravance Biopharma Inc (2025–2025)

Year-by-year Capital Reinvestment Ratio for Theravance Biopharma Inc from 2025 to 2025. See Theravance Biopharma Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2025 0.00x $238.54 Million $42.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow